open pharma

See the following -

Open source software is a viable model for the healthcare industry

Alice Gillet | L'Atelier | July 4, 2012

Technology company Clinovo develops open source software for the highly regulated clinical research industry. This new solution is becoming a legitimate and viable alternative to commercial solutions, and might help shape the future of the healthcare industry.

Read More »

OpenClinica And TraIT: A Dutch National Research Infrastructure

Jan-Willem Boiten | OpenClinica | August 5, 2013

Is it possible to set up an IT infrastructure for translational research for an entire country? The Dutch Translational Research IT (TraIT) project (http://www.ctmm-trait.nl/) believes it is. Admittedly, The Netherlands is not exactly the same size as China or the US, but nevertheless already 26 partners from industry and academia to collaborate in this consortium to organize, deploy, and manage a nationwide IT infrastructure for data and workflow management targeted specifically at the needs of translational research.

Read More »

OpenClinica At Netherlands CTMM Annual Event

Rob Rittberg | OpenClinica Blog | October 16, 2013

On September 12, 2013, The Center for Translational Molecular Medicine (CTMM) held their annual meeting at the Media Plaza, Jaarbeurs Utrecht in the Netherlands. The theme,  ‘Let’s talk about Value,’ celebrated the implementation of proven results in a clinical practice, the benefits they will bring for patients, and the real value they will add to society and the Dutch economy.

Read More »

Opening Up The Indian Rare Disease Market: An Interview With ORD India

Cameron | Total Orphan Drugs | March 20, 2014

We here at Total Orphan Drugs, as part of this month’s focus on emerging markets for the orphan drug industry, have been speaking to Harsha K Rajasimha of the newly formed Organization for Rare Diseases India (ORDI).  With a rare disease population estimated to be around 72,611,605 (more than the US and EU rare disease populations combined) the need for orphan treatments is huge, and with little in place so far, India represents a lucrative market to developers and pharma looking to expand their orphan operations.

Read More »

Pharmaceutical CEO Says His Cancer-Fighting Drugs Aren't For Poor People

Vivian Giang | PolicyMic | January 27, 2014

Big pharmaceutical companies constantly compete with one another to come up with the next "superstar" life-saving drug. But when the cure becomes a means of making money rather than a way to save lives, maybe they should refocus their mission statements.

Read More »

Pistoia Alliance Launches New Open Innovation Platform

Press Release | Pistoia Alliance, Qmarkets | August 4, 2014

The Pistoia Alliance has today launched its new online Interactive Project Portfolio Platform (IP3) in order to encourage the entire life sciences research community to generate and share new, innovative ideas and drive the creation of novel, collaborative solutions that break down barriers in life science R&D. Read More »

The Collateral Benefits of India's Open Source Drug Discovery Programme

Priyanka Pulla | Forbes India | April 9, 2014

India's Open Source Drug Discovery programme is struggling for lack of expertise and a research ecosystem. However, the programme's real contribution may be the creation of just such an ecosystem Read More »

TraIT OpenClinica attracts more than 300 users

Marinel Cavelaars | ctmm | January 31, 2014

In the two years since OpenClinica was adopted as the preferred data capture tool for the TraIT (Translational Research IT) platform, its user base on the TraIT server has grown from 15 clinical studies to over 60 clinical studies involving more than 300 users. Read More »

Upcoming Vote on the Biomedical R&D Treaty

Brian Till | The Atlantic | May 15, 2013

For almost a decade, the United States has been standing in the way of an idea that could lead to cures for some of the world's most devastating illnesses. The class of maladies is known as neglected diseases, and they almost exclusively affect those in the developing world. Read More »